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1.18.2 Inhibition Assay 
Marianne Jochum 
General 
The biomedical use of the low molecular-weight (Mr = 6500) proteinase inhibitor 
aprotinin (Trasylol®), from bovine tissue cells is based on its broad inhibitory specifi-
city. Major target enzymes are trypsin, chymotrypsin, plasmin, tissue kallikrein and 
plasma kallikrein. Hence, administration of aprotinin to patients is recommended as 
part of the therapeutic regimen of various diseases, in particular in shock syndromes, 
hyperfibrinolysis or acute pancreatitis (for review cf. [1]). Serum or plasma levels of 
aprotinin obtained after intravenous injection decline rather rapidly due to distribu-
tion of the inhibitor in the extracellular fluid and subsequent accumulation, primarily 
in the kidney [2, 3]. Therefore, one major prerequisite for the optimization of the 
proteinase inhibitor therapy is the quantitative assessment of the inhibitor levels in 
patients' plasma or other body fluids. 
Application of method: in biochemistry, clinical chemistry and pharmacology. 
Substance properties relevant in analysis: aprotinin can be exposed to solutions with 
extreme pH values [1], Hence, acid treatment of aprotinin-containing plasma samples 
allows a total recovery and thereby a specific measurement of aprotinin as the only 
tissue kallikrein inhibitor present in these specimens. 
Methods of determination: so far, aprotinin has been measured in biological samples 
by the trypsin inhibition assay [1 , 4] or by immunological methods [5, 6]. However, 
these assays are inappropriate for monitoring inhibitor levels in routine clinical 
diagnosis because of the limited specificity of the enzyme inhibition assay and the 
prolonged incubation (>40 h) necessary in the immunoassays. The enzymatic deter-
mination described here circumvents these difficulties and therefore can conveniently 
be used as a specific and rapid bedside control of high-dosage proteinase-inhibitor 
therapy [7]. 
An enzyme-linked immunosorbent assay was developed only recently ([8], cf. 
chapter 1.18.1) which provides a versatile means of measuring very precisely and rela-
tively rapidly (4 h) large numbers of aprotinin-containing samples from plasma and 
other body fluids. This assay is suitable for special purposes, e.g. for monitoring 
lower dose inhibitor therapy in retrospective studies. 
International reference method and standards: not yet available. 
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Assay 
Method Design 
Principle 
(a) Aprotinin + tissue kallikrein (excess) 
5 min 
aprotinin-tissue kallikrein + tissue kallikrein (remaining) 
(b) D-Val-Leu-Arg-4-NA + H 2 0 
tissue kallikrein (remaining) 
D-Val-Leu-ArgOH + 4-nitroaniline. 
After incubation of acid-treated plasma with tissue kallikrein (EC 3.4.21.35) in excess, 
the remaining amount of the enzyme is determined by its amidolytic activity on the 
substrate D-Val-Leu-Arg-4-NA (S-2266). The initial rate at which 4-nitroaniline is 
released is measured photometrically at 405 nm. 
The reaction rate decreases linearly with increasing concentration of aprotinin in 
the range of 20000 - 80000 K I U * per litre plasma. The concentration of aprotinin is 
calculated from a calibration curve prepared by diluting normal plasma to which 
aprotinin (2x 105 KIU/1) has been added before acid treatment. 
Optimized conditions for measurement: an enzyme activity of 1 K U * * is used in the 
assay mixture; taking Km into account, the substrate concentration of 0.15 mmol/1 
ensures minimal influence of substrate depletion. Pre-incubation of acid-treated apro-
tinin-containing samples with the enzyme for 5 min at pH 8.2 is sufficient to achieve 
complete complex formation. Since the kallikrein activity towards the chromogenic 
peptide substrate is increased by the addition of plasma, all dilutions of aprotinin-con-
taining plasma samples have to be performed with aprotinin-free plasma instead of 
buffer: in this way, the same amount of plasma (e.g. 25 ^1) is always added to the 
assay system. 
Temperature conversion factors: the assay should be performed at 37 °C. Conversion 
factors for other temperatures have not yet been determined. 
Equipment 
Spectrophotometer or spectral-line photometer capable of exact measurement at 
405 nm, provided with a thermostatted cuvette holder; water-bath, centrifuge (Eppen-
dorf 5412); recorder or stopwatch; semi-microcuvettes. 
* K I U biological kallikrein inhibitor unit (cf. [1]). 
** K U biological kallikrein unit (cf. [1]). 
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Reagents and Solutions 
Purity of reagents: all chemicals should be of the highest analytical grade commer-
cially available. 
Preparation of solutions (for about 280 determinations): all solutions in re-purified 
water (cf. Vol . I I , chapter 2.1.3.2). 
1. Buffer (Tris, 0.2 mol/1, pH 8.2): 
dissolve 24.2 g tris(hydroxymethyl)aminomethane in 800 ml water, adjust to pH 8.2 
with HCl , 1 mol/1 (approximately 100 ml), and dilute to 1000 ml with water 
(25 °C). 
2. Substrate solution (D-Val-Leu-Arg-4-NA, 1.5 mmol/1): 
dissolve 25 mg S-2266 (from ABKabiDiagnostics Stockholm, Sweden) in 28.8 ml 
water. 
3. Porcine pancreatic kallikrein solution* (10 6 KU/1): 
dissolve the lyophilized enzyme with sterile physiological saline (adjusted to pH 7.5 
with triethanolamine) to a stock solution of 106 K U / m l . Prepare further dilutions 
for the assay (5 x 104 KU/1 ^ 1 KU/20 freshly each day. 
4. Normal human plasma: 
take blood specimens from veins of at least ten healthy blood donors (9 vol blood 
and 1 vol sodium citrate solution, 0.1 mol/1). Prepare plasma by centrifugation at 
2000 g for 20 min at 4 ° C . Mix equal amounts of plasma from each donor and 
dispense in small volumes. Treat with perchloric acid (6) as described for samples 
under Collection and treatment of specimens. 
5. Aprotinin standard solutions: 
use ampoules with 2 x 105 KIU/10 ml, pH 5, from Bayer AG, Leverkusen; add 
10 |al (200 KIU) to 1 ml normal plasma (4) for preparation of the calibration curve. 
Dilute this stock solution (105 KIU/1) with aprotinin-free normal plasma (4) 
according to the following scheme: 
* Research product from Bayer AG, Wuppertal-Elberfeld. 
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Stock solution Normal plasma K I U K I U (x 103) 
(10 5 KIU/1) Hi per assay per 1 untreated 
ul plasma 
10 190 0.125 10 
10 90 0.25 20 
20 80 0.50 40 
30 70 0.75 60 
40 60 1.00 80 
50 50 1.25 100 
6. Perchloric acid solution (PCA, 30 g/1): 
dilute 8.57 ml 70% (w/v) PCA with 191.43 ml water. 
7. Potassium carbonate solution ( K 2 C 0 3 , 5 mol/1): 
dissolve 6.91 g K 2 C 0 3 in 8 ml water and dilute to 10 ml with water. 
Stability of solutions: store all solutions at 2 ° C to 8 ° C . Solutions (1) and (7) are stable 
for two months i f not contaminated with micro-organisms. Solution (2) is stable for 
six months i f prepared with sterile water and kept in the dark. Solution (3) is stable for 
at least two weeks. I f not contaminated, solutions (5) and (6) are stable indefinitely. 
Normal plasma (4) is stable for at least 3 - 4 months at - 20 °C or more than 6 months 
at - 7 0 ° C . Commercially available lyophilized normal plasma may also be used. 
Procedure 
Collection and treatment of specimens: take blood specimens from the vein without 
stasis (9 vol blood + 1 vol sodium citrate solution, 0.1 mol/1). Prepare plasma by 
centrifugation at 2000 g for 20 min at 4 ° C . 
Acid treatment of plasma samples: incubate plasma (e.g. 0.5 ml) for 10 min at 25 °C 
with an equal volume of PCA solution (6). Centrifuge for 10 min at 10000 g, 
neutralize ca. 0.980 ml supernatant with ca. 20 \i\ K 2 C 0 3 solution (7), keep at 4 ° C to 
8 °C for further 30 min and thereafter centrifuge again for 10 min. Freeze the resulting 
supernatant at - 2 0 ° C or below. 
Stability of aprotinin in the sample: aprotinin in plasma is stable at room temperature 
at least for 1 day or at 4 ° C for 2 days. Aprotinin solutions of pH < 4 should be used 
within a few hours. Neutralized aprotinin-containing plasma samples can be stored 
for 1 month at - 2 0 ° C or for 6 months at - 7 0 ° C . Repeated freezing and thawing 
(n = 10) has no influence on the inhibitory activity of aprotinin in plasma. 
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Details for measurements in other samples: the same procedure may be used for meas-
urements in serum and other specimens. 
Assay conditions: wavelength Hg 405 nm; light path 10 mm; final volume 1 ml; 
temperature 37 °C (thermostatted cuvette holder). Measure against air. Before starting 
the assay, adjust temperature of solutions to 37 °C. 
Establish a calibration curve using aprotinin solution (5) instead of sample. 
Measurement 
Pipette successively into 
the cuvette: 
blank sample concentration in assay 
mixture 
Tris buffer (1) 
normal plasma (4) 
sample or standard (5) 
kallikrein solution (3) 
0.855 ml 
0.025 ml 
0.020 ml 
0.855 ml 
0.025 ml 
0.020 ml 
Tris 171 mmol/1 
aprotinin up to 1250KIU/1 
kallikrein 1000 KU/1 
D-Val-Leu-Arg-4-NA 
0.15 mmol/1 
mix thoroughly with a plastic spatula, wait for 
5 min, 
substrate solution (2) 0.100 ml 0.100 ml 
mix and read absorbance each min or monitor the 
reaction on a recorder over a period of 5 min. 
I f the amount of aprotinin in the sample exceeds 1.0 K I U per assay, plasma samples 
must be diluted with aprotinin-free, acid-treated normal plasma (4). 
0.125 Ö.25 0.5 0.75 1.0 1.25 KJU/assay F i g * c a l i b r a ' i o n 
curve for the assay of apro-
10 20 40 60 80 100x103 KIU/I plasma tinin in plasma. 
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Calibration curve: calculate (&A/At)sampk in percent of (AA/At)blSink. the 
percent of free enzyme activities of the standards against their activity concentrations 
of aprotinin (Fig. 1). 
Calculation: the inhibitory activity of aprotinin in the sample (patients' plasma) is 
taken from the calibration curve. 
Validation of Method 
Precision, accuracy, detection limit and sensitivity: the within-run imprecision for 
aprotinin, 4 x 104 KIU/1 was 1.8-10.8% in 8 series; the between-series imprecision 
(n = 8) was 4.4%. The recovery for 2 x 104 to 8 x 104 KIU/1 (working range) was 
90 -125%. Data on accuracy are not available since standard reference material is not 
established yet. 
The detection limit is 0.125 K I U per assay, i.e. 104 KIU/1 of untreated plasma. 
Sensitivity is found to be AA/At = 0.002/min at 405 nm (Eppendorf photometer), 
the mean 1.23-fold increase caused by pooled plasma. With an individual increase in 
Sources of error: since kallikrein activity is increased 1.23-fold (n = 90; RSD = 
7.2%) by addition of acid-treated normal plasma, all dilutions of aprotinin-containing 
plasma samples must be made with aprotinin-free, acid-treated plasma. Plasma 
samples without acid treatment cannot be used because of a rather high and irregular 
stimulation of the kallikrein activity in the assay system. The same holds true for 
serum. Dilution of aprotinin-containing plasma samples with buffer or isotonic saline 
solution instead of plasma yields too low inhibitor concentrations. 
Occassionally, aprotinin-free plasma samples from a single individual may stimu-
late kallikrein activity to a lesser (up to 1.1-fold) or greater (up to 1.5-fold) extent than 
kallikrein activity lower than 1.15-fold or higher than 1.3-fold, the calibration curve 
and dilutions of aprotinin-containing plasma samples should be performed with the 
individual patient's plasma (pre-aprotinin infusion sample) instead of pooled plasma. 
Addition of NaN 3 to aprotinin-containing plasma as a preservative before acid 
treatment partly destroys the inhibitor activity during the subsequent procedure. 
Specificity: under the given conditions the substrate S-2266 is split specifically by the 
tissue kallikrein used in the assay. 
Therapeutic ranges: continuous i.v. infusion of 250000 K l U / h in polytraumatized 
patients resulted in a mean plasma concentration of 4.5 x 104 KIU/1 [7]. 
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